$1,318.00
This Market Spotlight report covers the Mesothelioma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Mesothelioma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
9 TREATMENT
9 Surgery
9 Chemotherapy
9 Radiotherapy
9 Immunotherapy
10 EPIDEMIOLOGY
14 MARKETED DRUGS
16 PIPELINE DRUGS
21 KEY UPCOMING EVENTS
22 KEY REGULATORY EVENTS
22 Alimta ANDA Products Hit Double Digits With Several Launches
23 PROBABILITY OF SUCCESS
24 LICENSING AND ASSET ACQUISITION DEALS
24 Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge
24 Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
24 Sanofi Hopes Owkin Can Aid Oncology Discovery
26 REVENUE OPPORTUNITY
27 CLINICAL TRIAL LANDSCAPE
28 Sponsors by status
29 Sponsors by phase
31 BIBLIOGRAPHY
32 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of mesothelioma, 2021–30
16 Figure 2: Overview of pipeline drugs for mesothelioma in the US
16 Figure 3: Pipeline drugs for mesothelioma, by company
17 Figure 4: Pipeline drugs for mesothelioma, by drug type
17 Figure 5: Pipeline drugs for mesothelioma, by classification
21 Figure 6: Key upcoming events in mesothelioma
23 Figure 7: Probability of success in the mesothelioma pipeline
27 Figure 8: Clinical trials in mesothelioma
27 Figure 9: Top 10 drugs for clinical trials in mesothelioma
28 Figure 10: Top 10 companies for clinical trials in mesothelioma
28 Figure 11: Trial locations in mesothelioma
29 Figure 12: Mesothelioma trials status
30 Figure 13: Mesothelioma trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of mesothelioma, 2021–30
13 Table 2: Incidence rates of mesothelioma, 2021–30
15 Table 3: Marketed drugs for mesothelioma
18 Table 4: Pipeline drugs for mesothelioma in the US
26 Table 5: Historical global sales, by drug ($m), 2017–21
26 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!